PlasmaGen Biosciences Bags INR 150 Cr to Scale International Plasma Therapeutics

The round, which included participation from HNI family offices, pharmaceutical entrepreneurs, and existing investors, values the company at over INR 1,500 crore.

Bengaluru-based PlasmaGen Biosciences, a biopharmaceutical company specializing in blood plasma-derived therapeutics, has raised INR 150 crore in a minority equity round led by ViNS Bioproducts. 

The round, which included participation from HNI family offices, pharmaceutical entrepreneurs, and existing investors, values the company at over INR 1,500 crore.

Founded in 2010, PlasmaGen has raised more than INR 600 crore in total funding to date. The fresh capital will be used to scale international operations, expand the product portfolio, and strengthen organizational capabilities.

“The past year has been transformational for PlasmaGen, marking a step change in the scale and reach of the company,” said Vivek V Kamath, CEO of PlasmaGen Biosciences. “With a clear plan and the support of this financing, we are well-positioned to turn our ambition into enduring impact for patients and partners worldwide.”

Investors have expressed strong confidence in PlasmaGen’s operating model, advanced manufacturing infrastructure, and long-term potential as a differentiated plasma biopharmaceutical platform. The company began commercial operations at a high-tech plasma fractionation facility in 2024, which is only the fifth such facility in India, and has recorded rapid revenue growth since.

Founder and Executive Chairman Vinod Nahar said, “From the outset, our objective has been to create a world-class, India-based plasma biopharmaceutical platform that delivers consistent quality and meaningful patient impact. This investment further strengthens PlasmaGen’s position as a long-term partner to healthcare systems and patients, both in India and internationally.”

PlasmaGen is preparing to enter global markets with identified distribution partners and ongoing regulatory approvals. Domestically, it continues to expand its presence with plasma-derived therapeutics addressing key unmet medical needs.

The company has also reinforced its leadership team, appointing Vivek V Kamath as CEO, Sethu Madhavan as COO (manufacturing and technical operations), and Arnav Jain as CFO to support its next growth phase.

Stay tuned for more such updates on Digital Health News